Advanced search
Search:  

1 - 7 of 7 results found for ETS2. Did you mean: ets

  1. Analysis of the fibroblastic growth factor receptor-RAS/RAF/MEK/ERK-ETS2/brachyury...

    http://iris.ucl.ac.uk/iris/publication/172947/3

  2. Transcriptional regulation of miR-196b by ETS2 in gastric cancer cells

    http://iris.ucl.ac.uk/iris/publication/854342/13

  3. Amplified segment in the 'Down syndrome critical region' on HSA21 shared between...

    Children with Down syndrome have a 20- to 50-fold increased risk of acute lymphocytic or myeloid leukaemia. Whole or partial gains of chromosome 21 have been described in multiple childhood leukaemias, and have recently been reported as a likely

    http://iris.ucl.ac.uk/iris/publication/789838/2

  4. Analysis of the fibroblastic growth factor receptor-RAS/RAF/MEK/ERK-ETS2/brachyury...

    Chordomas are rare primary malignant bone tumours that derive from notochord precursor cells and express brachyury, a molecule involved in notochord development. Little is known about the genetic events responsible for driving the growth of this

    http://iris.ucl.ac.uk/iris/publication/172947/2

  5. Unraveling the complexity of endocrine resistance in breast cancer by functional genomics.

    Despite the proven benefit of antiestrogen drugs in breast cancer treatment, resistant disease ultimately develops in advanced breast cancer. In this issue of Cancer Cell, Iorns et al. find that loss of CDK10 expression promotes resistance of cells

    http://iris.ucl.ac.uk/iris/publication/431855/2

  6. Identification of Arx targets unveils new candidates for controlling cortical interneuron...

    Mutations in the homeobox transcription factor ARX have been found to be responsible for a wide spectrum of disorders extending from phenotypes with severe neuronal migration defects, such as lissencephaly, to mild forms of intellectual disabilities

    http://iris.ucl.ac.uk/iris/publication/393800/2

  7. Multi-omics integration identifies key upstream regulators of pathomechanisms in...

    Background: Hypertrophic cardiomyopathy (HCM) is the most common genetic disease of the cardiac muscle, frequently caused by mutations in MYBPC3. However, little is known about the upstream pathways and key regulators causing the disease. Therefore,

    http://iris.ucl.ac.uk/iris/publication/1856467/1

  8. Page: 1